Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005874 · ClinicalTrials.gov registry record · Phase 2
Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas
A Phase 2 study, sponsored by Astex Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00005874 is a Phase 2 study that has completed, run by Astex Pharmaceuticals.
The verdict
NCT00005874, a Phase 2 study, has completed, sponsored by Astex Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have locally advanced or metastatic soft tissue sarcomas.
Interventions
- DRUG rubitecan
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-06 |
| Est. Completion | 2004-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005874
The ClinicalTrials.gov registry entry for NCT00005874 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Astex Pharmaceuticals, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rubitecan is the first listed.
NCT00005874 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005874 about?
NCT00005874 is a clinical study titled "Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have locally advanced or metastatic soft tissue sarcomas.
What is the current status of trial NCT00005874?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-06. Estimated completion is 2004-04.
What interventions are being tested in trial NCT00005874?
The interventions under investigation include: rubitecan (DRUG).
Who is sponsoring clinical trial NCT00005874?
This trial is sponsored by Astex Pharmaceuticals, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.